FortuneX Acquisition

This is the foundational document for tracking FortuneX's redemption calendar and trust economics: it establishes a roughly $10.10-per-share trust value, a 12-month search window starting at the offering closing, extension mechanics with shareholder redemption rights, and a 15% redemption limitation in the vote path. It also discloses significant sponsor incentives and conflicts, including nominal founder shares, overlapping management across multiple SPACs, and potential diversion of deal opportunities, all of which bear on whether and how a business combination gets completed.

The shortened 12-month deadline increases pressure to find a target or seek an extension, raising the risk of liquidation. The trust value of $10.05 per share is confirmed. The extensive conflicts mean management may present opportunities to other SPACs first, reducing FXAC's ability to secure a high-quality deal. The going concern qualification underscores the necessity of IPO proceeds for survival.

This filing sets the final terms for FXAC's IPO and trust mechanics. The trust is $10.05 per share, with a 12-month deadline from closing. No deal progress – the SPAC has not identified or contacted any target. Material conflicts of interest are disclosed: management (CEO McCabe and director nominees) serve on eight other SPAC boards (Yotta, Quetta, Black Hawk, Quartzsea, etc.), creating risk that potential targets may be allocated to other entities. The nominal $0.0068/share founder shares and the lack of a maximum redemption threshold also pose governance risks. The filing is the key reference for redemption and deadline tracking once the IPO closes.

The filing is the current, effective prospectus for FXAC's IPO. It provides definitive terms: 7,500,000 units at $10.00/unit, $10.05 per share in trust at closing (initial estimate), a 12-month deadline from closing to find a deal (with no limit on extensions by shareholder vote), and mandatory redemption rights for public shareholders in connection with a business combination or certain charter amendments. The trust per-share value is stated as $10.05, not $10.00. The filing also reveals the sponsor's nominal cost ($0.0068/share) for founder shares creating significant dilution risk for public investors and a strong incentive for the sponsor to close any deal. It details extensive conflicts of interest: the CEO/director sits on eight other SPAC boards, all actively searching for targets in the same $180M-$1B enterprise value range as FXAC.

This is the first complete prospectus for the SPAC IPO. It establishes the trust amount ($75,375,000), the initial per-share trust value ($10.00 gross, $10.05 per share including interest), the 12-month deadline (or shareholder-approved extensions), and the redemption mechanics. The reduction to a 12-month period and the explicit conflict-of-interest disclosure regarding Quartzsea are material changes that affect investor redemption timing and risk assessment. The document also reveals the sponsor's nominal cost basis ($0.0068 per founder share) and the significant dilution to public shareholders.

This is the foundational document for FXAC's redemption and liquidation mechanics once the IPO closes: public shareholders would be entitled to redeem their public shares for a pro rata share of the trust in connection with a business combination, an extension vote, or liquidation if no deal closes within 18 months. It also discloses sponsor conduct and conflicts: the sponsor paid only $25,000 for 3,694,429 founder shares, will hold about 30% of the post-offering shares, waives redemption rights on founder and private shares, is owed repayment of a $200,000 loan, and will receive $15,000 per month for administrative services. The underwriter is entitled to a $3,750,000 deferred fee from the trust on closing of a business combination. Management serves on eight other SPACs, creating potential target-allocation conflicts, and the prospectus highlights significant PRC-related regulatory risk. Investors should focus on whether and when the IPO closes, because that starts the combination clock.

What changed: A Form 3 insider ownership report submitted to the SEC, identifying FortuneX Acquisition Corp as the issuer, Daniel M. McCabe (director, Chairman and CEO) as the reporting person, and providing the accession number 0001829126-26-007215. The filing explicitly states 'No non-derivative transactions or holdings reported.' This indicates zero change in the Chairman and CEO’s direct beneficial ownership of the issuer’s securities during the reporting window. No purchases, sales, conversions, exercises, or transfers requiring Form 3 disclosure occurred. Why it matters: For investors tracking redemption deadlines, trust value, extensions, deal progress, and sponsor conduct, this routine regulatory submission confirms static insider equity positioning. The absence of transactional activity provides no new signal regarding the sponsor’s appetite for specific target verticals, anticipated voting behavior on potential extension proposals, or economic alignment with public shareholders ahead of redemptions. It merely fulfills baseline Section 16 ownership transparency obligations. The document contains no claims about customers, revenue, market size, strategy, technology, partnerships, litigation, or personnel beyond naming McCabe’s titles. It attributes no statements to any executive, advisor, or third party, and includes no financial figures other than the regulatory accession number. Consequently, it does not alter mechanical assumptions about the SPAC’s capital structure, path to a business combination, or governance posture. Investors relying on insider activity as a leading indicator of deal readiness or extension likelihood receive no fresh data from this filing.

What changed: Routine compliance exhibit (Form 3 initial statement of beneficial ownership). The filing identifies reporting person Sean Michael Deegan (director) and explicitly states that no non-derivative transactions or holdings are reported. Why it matters: This regulatory submission records zero insider share activity, meaning the redemption calendar, trust value trajectory, extension mechanics, target search status, and sponsor conduct remain entirely unaltered by this submission. The sole substantive item is the director-level personnel disclosure required upon assuming or confirming the position.

What changed: A Form 3 — insider ownership report. Per the filing text, reporting director Robert L. Labbe submitted 'No non-derivative transactions or holdings reported.' This introduces no adjustments to redemption mechanics, trust accounting, extension triggers, target search progress, or sponsor conduct. The document additionally contains no substantive disclosures regarding customers, revenue, market size, corporate strategy, technology, partnerships, litigation, or personnel beyond confirming FortuneX Acquisition Corp as the issuer and Labbe Robert L. as the reporting person. Why it matters: This is a routine Section 16(a) compliance exhibit verifying that insider equity positions remain unchanged. It does not alter the SPAC’s operational parameters, available trust reserves, or SEARCHING status. Investors tracking conversion windows, redemption thresholds, or merger negotiation timelines will find this submission provides zero delta on deal execution or capital preservation.

What changed: A Form 8-K current report and accompanying press release (Exhibit 99.1) announcing the commencement of separate trading for the company’s ordinary shares and warrants following the unbinding of those securities from their original unit structure. Per Item 8.01 of the filing, the Company announced that, with underwriter consent, holders may elect to separately trade the ordinary shares and warrants included in the units commencing on or about July 1, 2026. Units remaining together will continue trading under the symbol FXACU, while separated shares and warrants will trade under the symbols FXAC and FXACW, respectively. The disclosure specifies that only whole warrants will trade, no fractional warrants will be issued upon separation, and shareholders must direct their brokers to contact Continental Stock Transfer & Trust Company to execute the split. Why it matters: This filing reports a routine administrative capitalization update confirming the transition from listed units to underlying securities, which does not alter the redemption calendar, trust balance, or business combination deadline. As stated in the Company’s press release dated July 1, 2026, and attributed to Chief Executive Officer Daniel M. McCabe, the sole financial term introduced is that each whole warrant entitles the holder to purchase one ordinary share at an exercise price of $11.50 per share, subject to adjustment as described in the prospectus. There are no updates to deal progress, sponsor conduct, extension provisions, or shareholder redemption mechanics reported in this submission.

What changed: Form 8-K Current Report (Items 8.01 and 9.01) documenting the closing of the underwriters’ over-allotment option, supplementary private placements, and associated pro forma financial adjustments following the company’s initial public offering. The filing updates the capitalization table and trust mechanics to reflect the full exercise of the 45-day over-allotment option on May 29, 2026, adding 1,125,000 units and $11,250,000 in gross proceeds, plus a concurrent 15,000-unit private placement to the sponsor generating approximately $150,000. Consequently, the unaudited pro forma balance sheet increases 'Cash and investments held in Trust Account' to $87,148,790 and classifies 8,625,000 'Ordinary shares subject to possible redemption' at a fixed $10.10 per share. The deferred underwriting fee payable increased by $562,500 to a total of $4,312,500. All securities remain registered on Nasdaq: Units (FXACU), Ordinary Shares (FXAC), and Warrants exercisable at $11.50 per share (FXACW). Why it matters: This posting establishes the definitive public trust balance and share count preceding any business combination search. The Company explicitly states that '$87,112,500 ($10.10 per Unit) of the net proceeds from the sales of Units in the IPO, the Option Units and the Private Placements Unit on May 26, 2026 and May 29, 2026, were placed in a trust account with Continental Stock Transfer & Trust acting as trustee.' Underwriting economics are detailed in the pro forma entries, noting a cash commission of 0.33% on the over-allotment proceeds and a deferred liability representing 5% of the option units, alongside $1,450 in recorded administrative expenses for May 27–29 and $15,000 in professional audit fees. Interest income of $36,290 accrued within the trust was reclassified to temporary equity per the Company's accounting treatment. Signed and filed by Chief Executive Officer Daniel M. McCabe on June 8, 2026, the filing confirms standard SPAC structuring mechanics without announcing a target, extending the deadline, or altering sponsor conduct provisions.

What changed: Current Report on Form 8-K announcing the consummation of the initial public offering and concurrent private placement, accompanied by Exhibit 99.1 detailing the initial audited balance sheet and notes as of May 26, 2026. The Company states that on May 26, 2026, it consummated its IPO of 7,500,000 Units at $10.00 per Unit, generating $75,000,000 in gross proceeds. Concurrently, Sponsor FortuneX Investment Partners Limited purchased 297,500 Private Placement Units at $10.00 per unit for $2,975,000. The Company placed $75,750,000 of net proceeds into a Trust Account. Note 10 discloses that on May 27, 2026, underwriters notified the Company of their full exercise of the over-allotment option, closing on May 29, 2026 for $11,250,000, with the Sponsor simultaneously purchasing 15,000 supplemental private units for $150,000. Why it matters: For the redemption mechanics, the Company notes the Trust holds $75,750,000, which management anticipates equals $10.10 per public share, plus pro rata interest. Public shareholders may elect to redeem shares at a Business Combination vote or via tender offer. If a shareholder vote is utilized, a public shareholder and affiliates acting in concert are restricted from redeeming more than an aggregate of 15% of Public Shares without Company consent. Management confirms the Company has 12 months from IPO closing, until May 26, 2027, to consummate a Business Combination; missing this deadline triggers an automatic winding up, dissolution, and liquidation. As of May 26, 2026, the Company held $1,102,515 in working cash against $117,047 in current liabilities and an accumulated deficit of $(2,696,032). Both the independent auditor (Simon & Edward, LLP) and management express substantial doubt about the Company's ability to continue as a going concern pending a successful combination or extension. The Sponsor retains 3,694,429 Founder Shares and has contractually agreed to be liable if third-party vendor claims reduce the Trust below $10.00 per public share, barring valid waivers. The Company also commits to paying the Sponsor $15,000 monthly under an Administrative Services Agreement through liquidation or combination, and recognizes a deferred underwriting fee payable of $3,750,000 that will be paid solely from remaining Trust funds upon a Business Combination.

What changed: An 8-K Current Report filed by FortuneX Acquisition Corporation (FXAC) summarizing the closing of its initial public offering (IPO) and the simultaneous execution of ancillary agreements, including the underwriting agreement, warrant agreement, trust agreement, and insider letter. The filing reports the consummation of FXAC's IPO on May 26, 2026. Key mechanics: the Company sold 7,500,000 units initially and an additional 1,125,000 units upon the underwriters' full exercise of the over-allotment on May 28, 2026, for total gross proceeds of $86,250,000. The sponsor simultaneously purchased 260,000 private placement units for $2,600,000. The trust value per share is set at $10.05 from the IPO and private placement proceeds. The deadline to complete a business combination is 12 months from the IPO closing (May 26, 2027), extendable by special resolution. The filing also appoints three independent directors (Becky Fallon, Sean Michael Deegan, Robert Labbe) effective May 19, 2026. Why it matters: This is a standard IPO closing 8-K, but it is the most informative document filed for this pre-deal SPAC. It establishes all redemption mechanics, trust value, and the extension process. The trust holds approximately $10.05 per share, and the company has until May 2027 to find a target. Investors should note the sponsor's 3,694,429 founder shares are subject to forfeiture if the over-allotment is not fully exercised, which it was. The filing also confirms the sponsor agreed to vote in favor of a business combination and not redeem shares.

What changed: A Rule 424(b)(4) final prospectus for FortuneX Acquisition Corporation's initial public offering of 7,500,000 units at $10.00 per unit, each unit consisting of one ordinary share and one-half of one redeemable warrant, with the company stating it is a Cayman Islands blank check company with no target identified and no substantive discussions with any prospective target. FortuneX priced and launched its SPAC IPO, establishing the operative trust and redemption mechanics: $10.10 per public share will be deposited in the trust; the company has 12 months from closing to complete a business combination, with no limit on shareholder-approved extensions and redemption rights in connection with any extension; public shareholders may redeem at the trust value, subject to a 15% aggregate redemption cap if a shareholder vote path is used; the sponsor is purchasing 297,500 private units at $10.00 (up to 312,500 if over-allotment is exercised); warrants are exercisable at $11.50 per share beginning 30 days after a business combination; and the underwriters have a 45-day option for up to 1,125,000 additional units. The financial statements also disclose pre-effective changes: the combination period was reduced from 18 months to 12 months, trust funding was increased from $10.05 to $10.10 per share, private units were increased, and warrant terms were modified. Why it matters: This is the foundational document for tracking FortuneX's redemption calendar and trust economics: it establishes a roughly $10.10-per-share trust value, a 12-month search window starting at the offering closing, extension mechanics with shareholder redemption rights, and a 15% redemption limitation in the vote path. It also discloses significant sponsor incentives and conflicts, including nominal founder shares, overlapping management across multiple SPACs, and potential diversion of deal opportunities, all of which bear on whether and how a business combination gets completed.